Drug Profile
Research programme: virosomal adjuvanted influenza vaccine - ADImmune Corporation/Crucell
Alternative Names: virosomal adjuvanted influenza vaccine - Crucell; Virosomal influenza vaccine - CrucellLatest Information Update: 19 Jul 2012
Price :
$50
*
At a glance
- Originator ADImmune Corporation
- Developer Crucell
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 18 Jul 2012 Discontinued - Preclinical for Influenza virus infections in Japan (unspecified route)
- 18 Jul 2012 Discontinued - Preclinical for Influenza virus infections in Macau (unspecified route)
- 18 Jul 2012 Discontinued - Preclinical for Influenza virus infections in Taiwan (unspecified route)